Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Farmers Insurance
Colorcon
Baxter
Deloitte
Harvard Business School
Cantor Fitzgerald
McKesson
AstraZeneca

Generated: February 19, 2018

DrugPatentWatch Database Preview

PAXIL Drug Profile

« Back to Dashboard

When do Paxil patents expire, and what generic alternatives are available?

Paxil is a drug marketed by Apotex Technologies and is included in four NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fifty-eight patent family members in thirty-eight countries.

The generic ingredient in PAXIL is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.
Summary for PAXIL
Drug patent expirations by year for PAXIL
Pharmacology for PAXIL

US Patents and Regulatory Information for PAXIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-001 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-004 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-002 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-003 Dec 29, 1992 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-004 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-002 Feb 16, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-004 Dec 29, 1992 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-001 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-002 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-003 Oct 9, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PAXIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-005 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-002 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride SUSPENSION;ORAL 020710-001 Jun 25, 1997 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-005 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-005 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride SUSPENSION;ORAL 020710-001 Jun 25, 1997 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-002 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-002 Oct 9, 1998 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-004 Dec 29, 1992 ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-001 Oct 9, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PAXIL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 37.5 mg ➤ Subscribe 5/19/2009
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 9/9/2005
➤ Subscribe Oral Suspension 10 mg/5 mL ➤ Subscribe 2/10/2005

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Johnson and Johnson
Moodys
Mallinckrodt
Covington
McKesson
Accenture
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot